Evidence map›Paper›PMID 35159274›Full record

ArticleCells2022

Dysregulated PI3K Signaling in B Cells of CVID Patients.

Ina Harder, Matthias Münchhalfen, Geoffroy Andrieux, Melanie Boerries, Bodo Grimbacher, Hermann Eibel, Maria Elena Maccari, Stephan Ehl, Jürgen Wienands, Julia Jellusova and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Elevated IL-10 is Linked With the Expansion of T-betJournal of clinical immunology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ina HarderDepartment of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Matthias MünchhalfenInstitute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0002-9240-9342
Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-5389-9481
Melanie BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Bodo GrimbacherInstitute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Hermann EibelDepartment of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Maria Elena MaccariInstitute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.ORCID 0000-0001-6488-7622
Stephan EhlInstitute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.ORCID 0000-0002-9265-2721
Jürgen WienandsInstitute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0001-8278-7668
Julia JellusovaInstitute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Klaus WarnatzDepartment of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Baerbel KellerDepartment of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
University of Freiburg · DEUniversitätsmedizin Göttingen · DETUM Klinikum · DE

Funding

Deutsche Forschungsgemeinschaft TRR130 TP07, TP08, TP25, WA 1597/4-2, CRC 850 subprojects C9 and Z1, CRC1479 (Project ID: 441891347- S1), CRC 1160 (Project Z02), CRC1453 (Project ID 431984000 - S1) and TRR167 (Project Z01), GR1617/14-1/iPAD; SFB1160/2_B5; RESIST-EXC 2155-Project ID 3908Federal Ministry of Education and Research BMBF 01EO1303, MIRACUM within the Medical Informatics Funding Scheme (FKZ 01ZZ1801B), GAIN 01GM1910A
6 · The paper itself

Abstract

The altered wiring of signaling pathways downstream of antigen receptors of T and B cells contributes to the dysregulation of the adaptive immune system, potentially causing immunodeficiency and autoimmunity. In humans, the investigation of such complex systems benefits from nature's experiments in patients with genetically defined primary immunodeficiencies. Disturbed B-cell receptor (BCR) signaling in a subgroup of common variable immunodeficiency (CVID) patients with immune dysregulation and expanded T-bet

Indexed as

Common Variable ImmunodeficiencyPhosphatidylinositol 3-KinasesB-LymphocytesClass I Phosphatidylinositol 3-KinasesHumansPrimary Immunodeficiency DiseasesSignal TransductionTOR Serine-Threonine KinasesClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesAPDSB cellsBCR signalingCD21low B cellsCVIDFOXO1immune dysregulationmTORPI3KS6

Identifiers

PMID35159274
PMCPMC8834633
OpenAlexW4213230007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.